Spyre completes enrollment in SKYWAY trial for anti-TL1A therapy SPY072
Go back to Spyre completes enrollment in SKYWAY trial for anti-TL1A therapy SPY072| (NASDAQ: SYRE) | Delayed: 100.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $100.32 | 52 Week High | $ | |||
| Open | $100.32 | 52 Week Low | $ | |||
| Day High | $100.32 | P/E | N/A | |||
| Day Low | $100.32 | EPS | $ | |||
| Volume | 2,414 | |||||
